Pfizer and German biotechnology announced that, based on the complete results of clinical trials, their jointly developed neocrown vaccine has a 95% efficacy rate, which is comparable to that of Modena, another U.S. company that recently announced a 94.5% efficacy rate, and that the vaccine is safe and harmless. This indicates that the chances of a vaccine developed by at least one of the companies being injected into the arms of Americans years ago are greatly improved.
For ten days, the two groups competed fiercely to obtain marketing approval from the U.S. authorities and Western countries. The Chinese and Russian-developed neocrown vaccine is also now in the final stages of testing.
On Wednesday, the complete results showed that a total of 170 of the 44,000 volunteers who participated in the vaccine trial were diagnosed with infection, including 162 in the placebo group and only 8 in the vaccinated group, proving that Pfizer’s neocrown vaccine has a 95% efficacy rate.
Another piece of good news is that the Pfizer-Neocoron vaccine developed with the German biotech company was equally effective in men and women, age, ethnicity, and prevention, with over 94% efficacy in the high-risk group over the age of 65.
If this effectiveness is further confirmed in the population, it would make this new vaccine one of the most effective neo-crown vaccines in the world, comparable to the measles vaccine, but much more effective than the influenza vaccine, which has been shown to be between 19-60% effective in the latest figures.
In addition, the trial showed that only more than 2 percent of volunteers experienced side effects, such as fatigue in 3.8 percent of volunteers and headaches in 2 percent of volunteers.
Modena, which announced Monday that its vaccine was 94.5 percent effective, used the most modern ARN technology, with similar results as Pfizer, and in addition to being highly effective, none of the volunteers had any serious adverse reactions.
Since the end of July, Pfizer has conducted clinical trials on more than 43,000 volunteers from multiple countries, and the safety results have been positive.
Pfizer said it recently submitted a marketing application to the U.S. Medicine Bureau for approval, and experts quoted by AFP said the U.S. authorities should have no problem giving the green light to Pfizer’s trial New Crown vaccine. According to experimental reports, no safety problems have been found. Another head of the Trump administration’s action committee for the development of a new vaccine, Slavi, told AFP that it is very likely that the vaccine will be approved for marketing in December.
However, the U.S. Pharmacy Board will carefully evaluate data on the efficacy and safety performance of the vaccines developed by Pfizer and Modena, which are not currently available, and says it will try to be as transparent and open as possible.
Chinese Vaccines Aim for Third World Markets, Confidence Needs to be Raised
The United States, the European Union, Canada, Japan, and other wealthy countries have already ordered hundreds of millions of doses from one or both of the two groups developing these vaccines.
However, there is a difference in the storage and shipping of the vaccines developed by U.S. drugmaker Pfizer and Modena, which must be stored and shipped at -70 degrees Celsius, while Modena’s vaccine only needs to be stored at -20 degrees Celsius.
Chinese media reported that, compared to the two U.S. vaccines, which require ultra-low temperature storage, China’s Kexing’s inactivated Xeonguan vaccine can be stored in a refrigerator at room temperature of 2 to 8 degrees Celsius, which is more suitable for most third-world countries around the world that cannot provide ultra-low temperature storage.
However, the Chinese Neocrown vaccine, which is in Phase III clinical trials but has already been administered to many people in their own countries, has not yet been proven safe and effective. Since July of this year, China has been inoculating tens of thousands of employees of state-owned enterprises, government officials, and company executives with three of the country’s four candidate vaccines, which are still in the late stages of human trials.
The New York Times reported on July 18: “These vaccinators may be taking a big risk. People who have been vaccinated with ineffective vaccines may be taking risks because they think the vaccines work. They may be barred from getting another, better vaccine because they have already been vaccinated. There have been examples in the past of health risks from vaccines that have not been tested and proven effective.” “Any time there are reports of vaccine-related deaths or illnesses, it can rekindle distrust of vaccines. China spent years vowing to overhaul its domestic vaccine industry after the scandal came to light.”
According to the BBC, the size of the experimental or injected population released by the Chinese manufacturer is actually no less than the two vaccines developed in Europe and the United States. But experts have questioned the Chinese brand’s failure to release Phase 3 clinical trial data. Professor Jin Dongyan of the Department of Biochemistry at the University of Hong Kong Li Ka Shing Faculty of Medicine said that the most important thing to be done in China’s current vaccine research is to speed up the Phase 3 trials and get the data to speak for itself. The expert told the BBC, “To give vaccines to people before they have finished clinical trials is to smash your own feet with a stone.
China’s Kexing Biotech’s Phase 3 clinical trial in Brazil was halted twice, but soon resumed. China’s immediate neighbors, Myanmar and Vietnam, are also skeptical of the quality of Chinese vaccines.
Recent Comments